These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

929 related articles for article (PubMed ID: 23830212)

  • 1. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
    J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.
    Bonello L; Armero S; Ait Mokhtar O; Mancini J; Aldebert P; Saut N; Bonello N; Barragan P; Arques S; Giacomoni MP; Bonello-Burignat C; Bartholomei MN; Dignat-George F; Camoin-Jau L; Paganelli F
    J Am Coll Cardiol; 2010 Nov; 56(20):1630-6. PubMed ID: 20708365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N; Yin S; Sun Z; Xu X; Qin J
    Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests.
    Gremmel T; Kopp CW; Moertl D; Seidinger D; Koppensteiner R; Panzer S; Mannhalter C; Steiner S
    Thromb Res; 2012 May; 129(5):616-22. PubMed ID: 22154242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel.
    Fernando H; Bassler N; Habersberger J; Sheffield LJ; Sharma R; Dart AM; Peter KH; Shaw JA
    J Thromb Haemost; 2011 Aug; 9(8):1582-9. PubMed ID: 21696537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
    Tsantes A; Ikonomidis I; Papadakis I; Kottaridi C; Tsante A; Kalamara E; Kardoulaki A; Kopterides P; Kapsimali V; Karakitsos P; Lekakis J; Travlou A
    Platelets; 2012; 23(6):481-9. PubMed ID: 22646492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
    Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
    Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
    Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
    Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
    Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
    Gajos G; Zalewski J; Nessler J; Zmudka K; Undas A; Piwowarska W
    Kardiol Pol; 2012; 70(5):439-45. PubMed ID: 22623230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
    Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
    Mega JL; Hochholzer W; Frelinger AL; Kluk MJ; Angiolillo DJ; Kereiakes DJ; Isserman S; Rogers WJ; Ruff CT; Contant C; Pencina MJ; Scirica BM; Longtine JA; Michelson AD; Sabatine MS
    JAMA; 2011 Nov; 306(20):2221-8. PubMed ID: 22088980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.
    Zhang HZ; Kim MH; Han JY; Jeong YH
    Platelets; 2014; 25(4):285-91. PubMed ID: 23971745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.